Genus Full Year 2024 Earnings: EPS Misses Expectations

Genus (LON:GNS) Full Year 2024 Results

Key Financial Results

• Revenue: UK£668.8m (down 3.0% from FY 2023).
• Net income: UK£7.90m (down 76% from FY 2023).
• Profit margin: 1.2% (down from 4.8% in FY 2023).
• EPS: UK£0.12 (down from UK£0.51 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Genus EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 72%.

Looking ahead, revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the United Kingdom.

Performance of the British Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Valuation

Our analysis of these results suggests Genus may be undervalued based on 6 important criteria we look at. Click here to find out what a fair price for the stock might be and where analysts see the share price heading over the next year.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.